Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

(2016) Cameron T Durlacher et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237)

(2016) Jeroen A.C.M. Goos et al.   NUCLEAR MEDICINE AND BIOLOGY

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma

(2015) Allison Rosenthal et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis

(2015) Jiao Zhang et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

(2015) Paul M. Barr et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

(2015) Bohuslav Melichar et al.   LANCET ONCOLOGY

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

(2015) Gerald S. Falchook et al.   Drugs in research & development

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

(2015) Todd B. Sells et al.   ACS Medicinal Chemistry Letters

Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships

(2014) Karthik Venkatakrishnan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Abstract B216: Mass balance, routes of excretion and pharmacokinetics of investigational oral [14C]alisertib (MLN8237) in patients with advanced solid tumors or lymphoma.

(2014) X. Zhou et al.   MOLECULAR CANCER THERAPEUTICS

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

(2014) Daruka Mahadevan et al.   PLoS One

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells

(2014) Martin Michaelis et al.   PLoS One

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

(2013) Santhosh Palani et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2013) Kevin R. Kelly et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Aurora A kinase (AURKA) in normal and pathological cell division

(2012) Anna S. Nikonova et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

(2012) D. Mahadevan et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment

(2012) Wenqing Qi et al.   LEUKEMIA RESEARCH

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

(2011) Wenqing Qi et al.   BIOCHEMICAL PHARMACOLOGY

The potential role of Aurora kinase inhibitors in haematological malignancies

(2011) Sherif S. Farag   BRITISH JOURNAL OF HAEMATOLOGY

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD